Clinical efficacy of intramuscular vaccinia immune globulin: A literature review

Clinical Infectious Diseases

Volumn 39, Issue 6, 2004, Pages 819-826

  Hopkins, Robert J ^a,c   Lane, J Michael ^b  

^a DynPort Vaccine Company LLC   (United States)

^b CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^c Emergent Biosolutions   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN; SMALLPOX VACCINE; UNCLASSIFIED DRUG; VACCINIA ANTIBODY;

BURN; CHICKENPOX; DRUG EFFICACY; DRUG INDICATION; ECZEMA; ECZEMA VACCINATUM; EXPOSURE; HIGH RISK POPULATION; HUMAN; IMMUNE DEFICIENCY; INFECTION RISK; MEDICAL LITERATURE; MORBIDITY; MORTALITY; POSTVACCINAL ENCEPHALITIS; PREGNANCY; PRIORITY JOURNAL; PROPHYLAXIS; REVIEW; SKIN DISEASE; SMALLPOX; SUPERINFECTION; VACCINIA;

ANTIBODIES, VIRAL; HUMANS; IMMUNOGLOBULINS; INJECTIONS, INTRAMUSCULAR; SMALLPOX; VACCINIA; VACCINIA VIRUS;

EID: 4544324735     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/422999     Document Type: Review

References (82)

1. Grabenstein JD, Winkenwerder W Jr. US military smallpox vaccination program experience. JAMA 2003; 289:3278-82.
2. Update: adverse events following civilian smallpox vaccination - United States, 2003. MMWR Morb Mortal Wkly Rep 2003; 52:819-20.
3. Vaccinia immune Gglobulin (human) [package insert]. Glendale, CA: Baxter Healthcare, 1995.
4. Breman JG, Henderson DA. Current concepts: diagnosis and management of smallpox. N Engl J Med 2002; 346:1300-8.
5. Henderson DA, Inglesby TV, Bartlett JG, et al. Smallpox as a biological weapon: medical and public health management. JAMA 1999; 281:2127-37.
6. Redfield RR, Wright DC, James WD, Jones TS, Brown C, Burke DS. Disseminated vaccinia in a military recruit with human immunodeficiency virus (HIV) disease. N Engl J Med 1987; 316:673-6.
7. Bray M, Wright ME. Progressive vaccinia. Clin Infect Dis 2003; 36:766-74.
8. Bicknell W, James K. The new cell culture smallpox vaccine should be offered to the general population. Rev Med Virol 2003; 13:5-15.
9. Kesson AM, Ferguson JK, Rawlinson WD, Cunningham AL. Progressive vaccinia treated with ribavirin and vaccinia immune globulin. Clin Infect Dis 1997; 25:911-4.
10. Espmark JA. Which is the factual basis, in theory and clinical practice, for the use of vaccinia immune globulin for the prevention or attenuation of complications of smallpox vaccination. Vox Sang 1979; 36:121-8.
11. Cono J, Casey CG, Bell DM. Smallpox vaccination and adverse reactions: guidance for clinicians. MMWR Morb Mortal Wkly Rep 2003; 52:1-28.
12. Plotkin SA. Vaccination against cytomegalovirus, the changeling demon. Pediatr Infect Dis J 1999; 18:313-26.
13. Enserink M. Public Health: treating vaccine reactions - two lifelines, but no guarantees. Science 2002; 298:2313.
14. Finlayson JS. Immune globulins. Semin Thromb Hemost 1979; 6:44-74.
15. Hansen RM, Libnoch JA. Remission of chronic lymphocytic leukemia after smallpox vaccination. Arch Intern Med 1978; 138:1137-8.
16. Seth V, Malaviya AN, Gopalan PR, Ghai OP. Progressive vaccinia successfully treated with vaccinia immune globulins. Indian Pediatr 1978; 15:67-72.
17. Feery BJ. Adverse reactions after smallpox vaccination. Med J Aust 1977; 2:180-3.
18. Turkel SB, Overturf GD. Vaccinia necrosum complicating immunoblastic sarcoma. Cancer 1977; 40:226-33.
19. Barandum S, Skvaril F, Morell A. Prophylaxis and treatment of diseases by means of immunoglobulins. Monogr Allergy 1975; 9:39-60.
20. Pond GD. Case report of patient with progressive vaccinia in the presence of documented depression of both cellular and humoral immunity. Ariz Med 1972; 29:313-8.
21. Gray JA. The use of gamma-globulin. Practitioner 1971; 206:494-500.
22. Soothill JF, Rowe DS. Hypogammaglobulinaemia in the United Kingdom. V. Immuno-globulins in hypogammaglobulinaemia. Spec Rep Ser Med Res Counc 1971; 310:45-66.
23. Velev VK. On the production and application of human and animal immunoglobulins in Bulgaria. Prog Immunobiol Stand 1970; 4:121-4.
24. Keane JT, James K, Blankenship ML, Pearson RW. Progressive vaccinia associated with combined variable immunodeficiency. Arch Dermatol 1983; 119:404-8.
25. Stienlauf S, Shoresh M, Solomon A, et al. Kinetics of formation of neutralizing antibodies against vaccinia virus following re-vaccination. Vaccine 1999; 17:201-4.
26. Goldstein JA, Neff JM, Lane JM, Koplan JP. Smallpox vaccination reactions, prophylaxis, and therapy of complications. Pediatrics 1975; 55:342-7.
27. Neff JM, Lane JM, Fulginiti VA, Henderson DA. Contact vaccinia-transmission of vaccinia from smallpox vaccination. JAMA 2002; 288:1901-5.
28. Lane JM, Ruben FL, Neff JM, Millar JD. Complications of smallpox vaccination, 1968. N Engl J Med 1969; 281:1201-8.
29. Vaccinia (smallpox) vaccine: recommendations of the Immunization Practices Advisory Committee. MMWR Morb Mortal Wkly Rep 1991; 40(RR-14):1-10. Erratum in: MMWR Morb Mortal Wkly Rep 1992; 41:31.
30. Cardiac adverse events following smallpox vaccination - United States, 2003. MMWR Morb Mortal Wkly Rep 2003; 52:248-50.
31. Lane JM, Goldstein J. Evaluation of 21st-century risks of smallpox vaccination and policy options. Ann Intern Med 2003; 138:488-93.
32. Strongin RJ, Salinsky E. Who will pay for the adverse events resulting from smallpox vaccination? Liability and compensation issues. NHPF Issue Brief 2003; 12:1-15.
33. Fauci AS. Smallpox vaccination policy: the need for dialogue. N Engl J Med 2002; 346:1319-20.
34. Haim M, Gdalevich M, Mimouni D, Ashkenazi I, Shemer J. Adverse reactions to smallpox vaccine: the Israel Defense Force experience, 1991 to 1996: acomparison with previous surveys. Mil Med 2000; 165:287-9.
35. Schraeder TL, Campion EW. Smallpox vaccination: the call to arms. N Engl J Med 2003; 348:381-2.
36. Ketchie KG, Suter RE. Are you ready to carry out smallpox vaccine plans? ED Manag 2002; 14:137-9.
37. Koplan JP, Marton KI. Smallpox vaccination revisited: some observations on the biology of vaccinia. Am J Trop Med Hyg 1975; 24:656-63.
38. Kemper AR, Davis MM, Freed GL. Expected adverse events in a mass smallpox vaccination campaign. Eff Clin Pract 2002; 5:84-90.
39. Frey SE, Couch RB, Tacket CO, et al. Clinical responses to undiluted and diluted smallpox vaccine. N Engl J Med 2002; 346:1265-74.
40. Bartlett JG. Smallpox vaccination and patients with human immunodeficiency virus infection or acquired immunodeficiency syndrome. Clin Infect Dis 2003; 36:468-71.
41. Smallpox vaccine adverse events monitoring and response system for the first stage of the smallpox vaccination program. MMWR Morb Mortal Wkly Rep 2003; 52:88-9, 99.
42. Smallpox vaccine adverse events among civilians - United States, January 24-February 18, 2003. MMWR Morb Mortal Wkly Rep 2003; 52:136.
43. Smallpox vaccine adverse events among civilians - United States, February 18-24, 2003. MMWR Morb Mortal Wkly Rep 2003; 52:156-7.
44. Smallpox vaccine adverse events among civilians - United States, February 25-March 3, 2003. MMWR Morb Mortal Wkly Rep 2003; 52:180-1.
45. Smallpox vaccine adverse events among civilians - United States, March 4-10, 2003. MMWR Morb Mortal Wkly Rep 2003; 52:201-3.
46. Copeman PW, Wallace HJ. Eczema vaccinatum. Br Med J 1964; 5414:906-8.
47. Brainerd HD, Hanna L, Hawetz E. Methisazone in progressive vaccinia. N Engl J Med 1967; 276:620-2.
48. Fekety FR, Malawista SE, Young D. Vaccinia gangrenosa in chronic lymphatic leukemia. Report of a case with recovery following the use of vaccinia immune globulin. Arch Intern Med 1962; 109:205-8.
49. Freed ER, Duma RJ, Escobar MR. Vaccinia necrosum and its relationship to impaired immunologic responsiveness. Am J Med 1972; 52:411-20.
50. Fulginiti VA, Kempe CH, Hathaway WE, et al. Progressive vaccinia in immunologically deficient individuals. Birth Defects 1968; 4:129-51.
51. Feery B. The efficacy of vaccinial immune globulin: a 15-year study. Vox Sang 1976; 31(Suppl 1):68-76.
52. Gispen R, Lansberg HP, Nanning W. The effect of antivaccinial gamma globulin on smallpox vaccination in view of a proposed attempt to prevent postvaccinal encephalitis. National Institute of Public Health, Utrecht, and Department of Preventive Medicine Royal Netherlands Army Medical Corps, The Hague, Netherlands, 1955.
53. Greenberg M. Complications of vaccination against smallpox. Am J Dis Child 1948; 76:492-502.
54. Hallett P. A survey of complications to smallpox vaccination. Med J Austral 1969; 1:898-901.
55. Hobday TL. Antivaccinial gammaglobulin in the control of smallpox. Lancet 1962; 1:907-8.
56. Kabat EA. Uses of hyperimmune human gamma globulin. N Engl J Med 1963; 269:247-54.
57. Kempe CH, Berge TO, England B. Hyperimmune vaccinal gamma globulin: source, evaluation, and use in prophylaxis and therapy. Pediatrics 1956; 18:177-88.
58. Kempe CH, Benenson AS. Smallpox and vaccinia. Pediatr Clin North Am 1955; 62:19-32.
59. Kempe CH. Studies on smallpox and complications of smallpox vaccination. Pediatrics 1960; 26:176-89.
60. Kempe CH, Bowles C, Meiklejohn G, et al. The use of hyperimmune gamma-globulin in the prophylaxis of smallpox. Bull World Health Org 1961; 25:41-8.
61. Kempe CH. An evaluation of risks of smallpox vaccination in United States. Abstracts of the Am Pediatric Soc 1965; 67:1017-22.
62. Lane JM, Ruben FL, Neff JM, Millar JD. Complications of smallpox vaccination, 1968: results of ten statewide survey. J Infect Dis 1970; 122:303-9.
63. Marennikova SS. The use of hyperimmune antivaccinia gamma-globulin for the prevention and treatment of smallpox. Bull World Health Org 1962; 27:325-30.
64. Nanning W. Prophylactic effect of anti-vaccinia gamma-globulin against post-vaccinal encephalitis. Bull World Health Org 1962; 27:317-24.
65. Neff JM, Lane JM, Pert JH, et al. Complications of smallpox vaccination. I. National survey in the United States, 1963. N Engl J Med 1967; 276:125-32.
66. Ruben FL, Lane JM. Ocular vaccinia: an epidemiologic analysis of 348 cases. Arch Ophthalmol 1970; 84:45-8.
67. Sharp JC, Fletcher WB. Experience of anti-vaccinia immunoglobulin in the United Kingdom. Lancet 1973; 1:656-9.
68. Semba RD. The ocular complications of smallpox and smallpox immunization. Arch Ophthalmol 2003; 121:715-9.
69. Sussman S, Grossman M. Complications of smallpox vaccination: effects of vaccinia immune globulin therapy. J Pediatr 1965; 67:1168-73.
70. Update: adverse events following civilian smallpox vaccination - United States, 2003. MMWR Morb Mortal Wkly Rep 2003; 52:419-20.
71. Update: adverse events following civilian smallpox vaccination - United States, 2003. MMWR Morb Mortal Wkly Rep, 2003; 52:444-6.
72. Wharton M, Strikas RA, Harpaz R, et al. Recommendations for using smallpox vaccine in a pre-event vaccination program: supplemental recommendations of the Advisory Committee on Immunization practices and the Healthcare Infection Control Practices Advisory Committee. MMWR Recomm Rep 2003; 52(RR-7):1-16.
73. Turnbull H, McIntosh J. Encephalomyelits following vaccination. British J Exper Path 1926; 7:181-222.
74. De Vries E. Postvaccinial perivenous encephaltis. Amsterdam: Elsevier, 1959.
75. Ellis P, Winograd L. Ocular vaccinia: a specific treatment. Arch Opthalmol 1962; 68:600-9.
76. Fulginiti VA, Winograd LA, Jackson M, Ellis P. Therapy of experimental vaccinal keratitis. Arch Ophthal 1965; 74:539-44.
77. Centers for Disease Control and Prevention. Smallpox vaccination and adverse reactions: guidance for clinicians. MMWR Morb Mortal Wkly Rep 2003; 52:1-28.
78. Engler RJ, Kenner J, Leung DY. Smallpox vaccination: risk considerations for patients with atopic dermatitis. J Allergy Clin Immunol 2002; 110:357-65.
79. Hopkins R, Kramer W, Blackwelder W, et al. Safety and pharmacokinetic evaluation of intravenous vaccinia immune globulin in healthy volunteers. Clin Infect Dis 2004; 39:759-66 (in this issue).
80. Strebel PM, Papania MJ, Halsey NA. Measles. In: Plotkin SA, Orenstein WO, eds. Vaccines. 4th ed. Philadelphia: WB Saunders, 2004:389-440.
81. Plotkin SA, Reef S. Rubella vaccine. In: Plotkin SA, Orenstein WO, eds. Vaccines. 4th ed. Philadelphia: WB Saunders, 2004:707-43.
82. Gershon AA, Takhashi M, Seward J. Varicella vaccine. In: Plotkin SA, Orenstein WO, eds. Vaccines. 4th ed. Philadelphia: W.B. Saunders, 2004:783-823.